Categoria: Novità
-
TRANSMISSION
Jie Zhou et al. Viral emissions into the air and environment after SARS-CoV-2 human challenge: a phase 1, open label, first-in-human study The Lancet, June 2023 ; doi.org/10.1016/S2666-5247(23)00101-5 Abstract Effectively implementing strategies to curb SARS-CoV-2 transmission requires understanding who is contagious and when. Although viral load on upper respiratory swabs has commonly been used to infer…
-
PREVENTION – PUBLIC HEALTH
Daniel Pan et al. Are clinical outcomes from COVID-19 improving in ethnic minority groups? The Lancet, July 2023; doi.org/10.1016/j.eclinm.2023.102091 Abstract Disproportionately worse COVID-19 clinical outcomes in people from ethnic minority groups have been a concern since early in the pandemic.1 Now as time progresses, it may be useful to look back at the evolving evidence…
-
CLINICAL FEATURES AND MORTALITY
Sho Nakakubo et al. Associations of COVID-19 symptoms with omicron subvariants BA.2 and BA.5, host status, and clinical outcomes in Japan: a registry-based observational study The Lancet, June 2023 ; doi.org/10.1016/S1473-3099(23)00271-2 Abstract Previous SARS-CoV-2 infection and vaccination, coupled with the rapid evolution of SARS-CoV-2 variants, have modified COVID-19 clinical manifestations. We aimed to characterise the clinical…
-
DIAGNOSTIC
Renelle Myers et al. Breath testing for SARS-CoV-2 infection Lancet, April 2023; doi.org/10.1016/j.ebiom.2023.104584 Abstract From a public health perspective, the identification of individuals with mild respiratory symptoms due to SARS-CoV-2 infection is important to contain the spread of the disease. The objective of this study was to identify volatile organic compounds (VOCs) in exhaled breath…
-
PROGNOSIS
Martin Potts et al. Proteomic analysis of circulating immune cells identifies cellular phenotypes associated with COVID-19 severity Cell, May 2023 ; doi.org/10.1016/j.celrep.2023.112613 Abstract Certain serum proteins, including C-reactive protein (CRP) and D-dimer, have prognostic value in patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Nonetheless, these factors are non-specific, providing limited mechanistic insight into the…
-
TREATMENT, EFFICACY-ADVERSE EVENTS AND DRUG RESISTENCE
Brian E. McGarry et al. Monoclonal Antibody and Oral Antiviral Treatment of SARS-CoV-2 Infection in US Nursing Homes JAMA, July 2023; doi:10.1001/jama.2023.12945 Abstract Nursing home residents are at elevated risk for severe infection from SARS-CoV-2,1 making them a priority for antiviral treatment.2 Although oral antiviral use has been found to be greater in nursing homes…
-
Corona testing positivy rates-Journal of American Medical Association (JAMA)
—
in NovitàNasal_swabs.pptx